Skip to main content

Table 1 Summary of perioperative cardiac arrest (PERIOPCA) recommendations

From: In-hospital cardiac arrest: evidence and specificities of perioperative cardiac arrest

PICO

Recommendation

ETCO2 as a prognosis tool of cardiac arrest

In patients with PERIOPCA, it may be reasonable to maintain an ETCO2 ≥ 10 mmHg during advanced life support. However, ETCO2 should be evaluated in the context of the patient’s clinical status and individualized targets may be necessary considering the cause of arrest, the degree of hypoxia, the quality of CPR and time to ROSC (COR/LOE: IIb/C-EO)

Monitoring physiological parameters during CPR

In adults with cardiac arrest in the perioperative setting, the use of physiological feedback may be reasonable to increase CPR quality and improve short- and long-term outcome (COR/LOE: IIb/C-EO)

Chest compression or defibrillation strategy for Ventricular Fibrillation (VF) or Pulseless Ventricular Tachycardia (pVT)

In adult patients with PERIOPCA, ventricular fibrillation/pulseless ventricular tachycardia should be defibrillated within 3 min after the onset of the arrest (COR/LOE: I/C-LD). The use of AEDs in patients with ventricular fibrillation/pulseless ventricular tachycardia can be useful for improving survival (COR/LOE: IIa/C-LD). It is not recommended to defibrillate patients with ventricular fibrillation/pulseless ventricular tachycardia lasting more than 3 min without prior chest compressions (COR/LOE: III/C-LD)

Timing of administration of epinephrine

In adult patients with PERIOPCA, epinephrine administration after the 3rd shock can be beneficial (COR/LOE: IIa/C-LD)

Standard-dose epinephrine (SDE) versus low-dose epinephrine (LDE) or high-dose epinephrine (HDE)

In patients with PERIOPCA, it may be reasonable to administer 1 mg epinephrine for improving coronary perfusion pressure (COR/LOE: IIb/C-EO)

No vasopressor versus epinephrine, or vasopressin

In patients with PERIOPCA, it may be reasonable to administer epinephrine every 3–5 min (COR/LOE: IIb/C-EO)

Antiarrhythmic drugs for cardiac arrest

In adult patients with PERIOPCA, it is recommended to administer amiodarone or lidocaine for the treatment of ventricular fibrillation/pulseless ventricular tachycardia (COR/LOE: I/C-LD). Magnesium is not indicated for the treatment of ventricular fibrillation/pulseless ventricular tachycardia in the perioperative setting (COR/LOE: III/C-LD)

Timing of administration of anti-arrhythmic

In adult patients with perioperative ventricular fibrillation/pulseless ventricular tachycardia, it might be reasonable to administer amiodarone or lidocaine after the 3rd shock (COR/LOE: IIb/C-EO)

Ventilation rate during continuous chest compressions

In adult patients with PERIOPCA and a secure airway, a ventilation rate of 10 breaths/min during CPR may be reasonable (COR/LOE: IIb/C-EO)

Cardiac arrest associated with pulmonary embolism

In adult patients with PERIOPCA due to pulmonary embolism or suspected pulmonary embolism, early consideration of thrombolysis and CPR duration of at least 60–90 min with or without the use of a mechanical chest compression device may be reasonable before terminating resuscitation attempts (COR/LOE: IIb/C-LD). The emergency treatment option among fibrinolytic therapy, surgical, or mechanical thrombectomy should be selected based on timing and available expertise, since no clear benefit of one approach over the other has been demonstrated

Cardiac arrest during pregnancy

In pregnant women with PERIOPCA, the effectiveness of any special interventions, compared to standard measures, is uncertain, except probably for manual uterine displacement during chest compressions (COR/LOE: IIb/C-EO). In pregnant women with PERIOPCA due to suspected or proven pulmonary embolism, it may be reasonable to use thrombolysis or other measures to remove clot (e.g., surgical or percutaneous pulmonary embolectomy) (COR/LOE: IIb/C-EO). Extracorporeal membrane oxygenation may be considered as an acceptable salvage therapy for pregnant and postpartum patients with PERIOPCA or those with critical cardiac or pulmonary illness (COR/LOE: IIb/C-EO)

Opioid toxicity

In patients with PERIOPCA due to opioid toxicity, it might be reasonable to administer specific agents in addition to advanced life support (COR/LOE: IIb/C-EO)

Epinephrine, vasopressin, steroids, and their combination during or after CPR

In adult patients with PERIOPCA, it is reasonable to administer corticosteroid or mineralocorticoid or the combination of vasopressin, epinephrine, and steroids during/after CPR to increase ROSC (COR/LOE: IIa/B-R). In these patients, these drugs can be useful for improving survival to discharge with good functional outcome (COR/LOE: IIa/B-R)

Lipid therapy for cardiac arrest

In adult patients with PERIOPCA due to confirmed or suspected LAST, it may be reasonable to use lipid therapy (COR/LOE: IIb/C-LD)

Ultrasound during CPR

In patients with PERIOPCA, it may be reasonable to use point-of-care ultrasound to improve CPR and increase survival rates (COR/LOE: IIb/C-EO)

ECPR versus manual or mechanical CPR

In adult patients with PERIOPCA, it may be reasonable to use ECPR as a rescue therapy when CPR has failed to provide ROSC or non-sustained ROSC (COR/LOE: IIb/C-LD)

Postresuscitation hemodynamic support

In patients with ROSC after PERIOPCA, it may be reasonable to target the hemodynamics goals to optimize tissue perfusion as indicated by an adequate urine output (1 ml/kg/h) and normal or decreasing plasma lactate values, taking into consideration the patient’s normal blood pressure, the cause of the arrest and the severity of any myocardial dysfunction (COR/LOE: IIb/C-EO)

Postresuscitation antiarrhythmic drugs

In the perioperative setting, it may be reasonable to administer antiarrhythmics immediately after ROSC to treat postresuscitation arrhythmias, especially in refractory cases, and prevent recurrences (COR/LOE: IIb/C-EO)

Postresuscitation permissive hypercapnia

In patients with ROSC after PERIOPCA, a lung-protective ventilation strategy (reducing tidal volume, plateau pressure, and driving pressure) and mild hypercapnia (PaCO2 of 40–50 mmHg) might be reasonable for improving outcome (COR/LOE: IIb/C-EO)

Postresuscitation target of PaO2

In patients with PERIOPCA, it may be reasonable to maintain normoxemia and avoid hyperoxemia (PaO2 goal of < 200 mmHg) in order to improve short and long-term outcome (COR/LOE: IIb/C-EO)

Targeted temperature management

In comatose patients with PERIOPCA, it may be reasonable to maintain normothermia in order to improve short and long-term outcome (COR/LOE: IIb/C-EO). Potential neurological benefit should be balanced against the hemorrhagic risk related to hypothermia (< 37 °C) in this surgical setting

Prognostication in comatose patients treated with hypothermic targeted temperature management

In patients with PERIOPCA and ROSC, it may be reasonable to use a multimodal strategy for prognostication, giving emphasis on allowing sufficient time for neurological recovery and to enable sedatives/paralytics to be cleared (COR/LOE: IIb/C-EO)

  1. PERIOPCA perioperative cardiac arrest, CPR cardio-pulmonary resuscitation, ECPR extracorporeal cardio-pulmonary resuscitation, ROSC return of spontaneous circulation, COR class of recommendation, EO expert opinion, LD limited data, LOE level of evidence